BRC Biotechnology

What BRC Biotechnology does

BRC Biotechnology (博瑞策生物技术 (上海) 有限公司) is a Shanghai-headquartered biosafety testing services provider founded in 2022 that supports biopharmaceutical developers across the full biological drug development lifecycle. The company operates more than 16,000 square meters of cGMP- and BSL-2-compliant laboratory and training facilities split between Shanghai (Pudong Free Trade Zone) and Suzhou, holding EU GMP QP, FDA FEI Number, ISO9001:2015, BSL-2, and CMA certifications. Its service portfolio addresses regulatory testing requirements for antibodies and recombinant proteins, vaccines, nucleic acid drugs, cell and gene therapies, oncolytic viruses, stem cells, and exosomes, covering IND- and BLA-stage submissions as well as commercial batch release.

The technology backbone consists of six integrated testing platforms — molecular biology (PERT detection, GMP Sanger sequencing), immunology (ELISA, Western blot, affinity assays), microbiology (sterility, mycoplasma, mycobacteria), virology (virus production/detection, replication-competent lentivirus), cell biology (cell banking, clonality, genetic stability), and animal science (ABSL-2 studies, humanized animal models). Differentiated proprietary capabilities include the NGenius™ high-throughput sequencing platform for GMP-grade adventitious virus detection, TLA (Targeted Locus Amplification) sequencing for clonal verification and gene integration site analysis, and a catalog of more than 20 ready-to-use residual nucleic acid detection kits (E.coli DNA, CHO host cell, HEK293 host cell). The company has also established strategic collaborations with Bio-Rad, Thermo Fisher Scientific, and USP China, and was recognized with the 2024 Pudong New Area Innovation and Entrepreneurship Award.

BRC generates revenue through project-based professional services contracts for laboratory testing, regulatory compliance consulting, and supply of detection kits, sold on a quote-based engagement model to biopharmaceutical enterprise clients. Go-to-market is enterprise field sales with dedicated project management and technical consultation, supplemented by industry conference participation (IBQC, EBC, XDC New Drug Conference), WeChat thought-leadership content, webinars, and hosting of satellite symposiums on biologics quality and cross-border compliance. The company is privately held, has raised approximately $28 million across two disclosed funding rounds (Legend Capital Series A in July 2023, Cenova-led Series B in December 2025), and employs 51–100 staff.

Name

BRC Biotechnology

Legal name

博瑞策生物技术（上海）有限公司

Website

https://brcgroup.cn

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

BRC Biotechnology is a Shanghai-based biosafety testing CRO serving biopharmaceutical developers with cGMP+BSL-2 compliant quality and safety testing across six integrated platforms spanning antibodies, vaccines, cell and gene therapies, and nucleic acid drugs.

Ownership category

akta.pro rank

Product category

Biosafety Testing Services

NAICS

Testing Laboratories and Services (54138), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability) (HLAAABAK)

akta.pro secondary industries

Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK), Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Biosafety testing services
• Biopharmaceutical quality control
• CGMP compliance testing
• Cell bank characterization
• Adventitious virus detection

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Biosafety Testing Services: Professional laboratory testing services for biological drug quality and safety compliance, including cell bank characterization, virus clearance studies, batch release testing, and adventitious agent detection. Services are provided on a project contract basis with regulatory compliance support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BRC Biotechnology provides cGMP+BSL-2 compliant biosafety testing services for biological drugs, spanning molecular biology, immunology, microbiology, virology, cell biology, and animal science disciplines. Its service portfolio includes cell bank characterization, virus clearance studies, batch release testing, adventitious agent detection, and GMP-grade cell banking, supported by proprietary platforms such as the NGenius™ high-throughput sequencing virus detection system and TLA-based cell line analysis, alongside more than 20 ready-to-use residual nucleic acid detection kits.

Product overview

BRC Biotechnology offers a unified platform of biosafety testing services for biological drugs, comprising multiple integrated service modules. The core offerings include biological drug quality and safety testing services covering antibodies, vaccines, nucleic acid drugs, cell and gene therapies (CGT), oncolytic viruses, stem cells, and exosomes. The portfolio includes a rapid ready-to-use detection kit development platform with over 20 residual nucleic acid detection products (E.coli, CHO, HEK293), new service platforms featuring TLA technology and humanized animal models, GMP-grade bacterial/cell banking and preservation, compliant cell line characterization services, and comprehensive environmental monitoring. The six integrated testing platforms (molecular biology, immunology, microbiology, virology, cell biology, animal science) work together to provide end-to-end biological drug safety evaluation. Recent addition includes NGenius™ for GMP-grade adventitious virus detection via high-throughput sequencing.

Differentiator

Problem solved

Functional benefit

Products and services

• Biological Drug Quality and Safety Testing Services Comprehensive biosafety testing services for biological drugs and novel therapies, covering antibodies, vaccines, nucleic acid drugs, cell and gene therapy products, oncolytic viruses, stem cells, and exosomes. Targeted at biopharmaceutical companies needing IND/BLA-grade safety data.
• Cell Line Characterization Services

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Bio-RadcoreStrategic or Co-development Partner · 1 March 2023Strategic collaboration with Bio-Rad focusing on cell and gene therapy safety assessment from a regulatory perspective. Joint educational initiatives and industry symposiums on CGT regulatory compliance.
• Thermo Fisher ScientificminorStrategic or Co-development PartnerParticipation in industry研讨会 (seminars) and knowledge sharing on gene therapy technology and industrialization development trends.
• USP (United States Pharmacopeia)coreStrategic or Co-development PartnerExchange and collaboration with USP China headquarters on pharmacopeia standards and biological drug quality control methodologies.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pharmaron: China-headquartered CRO with strong biologics and CGT testing capabilities, including cell banking, biosafety, and viral clearance. Direct competitor in the Chinese market and increasingly a global competitor in biosafety testing for novel modalities.
• GenScript ProBio: GenScript's CDMO arm offers cell banking, viral vector manufacturing, and biosafety testing services for biologics and CGT, making it a direct China-based peer in cell line characterization and viral safety testing.

Broad incumbents

• Charles River Laboratories: Global CRO with a major biosafety testing and cell banking business for biologics and CGT developers. Directly comparable to BRC in service scope (cell line characterization, viral clearance, mycoplasma, sterility) but at much larger global scale and with deeper regulatory track record.
• Eurofins Scientific: Global testing services group with BioPharma Product Testing capabilities spanning biosafety, viral clearance, cell banking, and release testing. Comparable to BRC across nearly all testing modalities, with established FDA/EU GMP credentials and broader geographic reach.
• SGS: SGS Life Sciences provides biosafety, viral clearance, and biologics release testing services globally. Comparable to BRC in testing depth, with a comparable focus on cGMP-compliant testing for biopharma and a presence in China.
• WuXi Biologics Testing Division: WuXi Biologics offers comprehensive biologics testing and biosafety services as part of its larger CRO/CDMO platform, making it the most direct Chinese competitor in cell bank characterization, virus clearance, and batch release testing for antibodies, CGT, and vaccines.
• Labcorp (formerly Covance): Labcorp's Biopharma Laboratory Services provides viral clearance, biosafety, and cell banking services for biologics developers. Comparable to BRC in core biosafety testing offerings, with deeper global regulatory experience.

Emerging players

• Vironova (part of NanoImaging Services): Provides viral safety and characterization services for gene therapy and vaccine developers, including viral vector analytics — overlapping with BRC's virology platform and AAV/lentiviral testing services.
• Cergentis: Specialist in TLA (Targeted Locus Amplification) sequencing for cell line characterization, clonality, and genetic stability — directly comparable to BRC's TLA service offering for cell line development and gene integration site analysis.
• Vela Diagnostics: Provides molecular and NGS-based diagnostic and safety testing services for infectious diseases and biopharma applications, with overlap to BRC's NGenius™ HTS-based adventitious virus detection approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BRC Biotechnology